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ABSTRACT
AnewPCR-basedmethod that exploits differences
in gyrB gene sequences was developed to
distinguish between Acinetobacter baumannii and
Acinetobacter genomic sp. 13TU. Among 118 clini-
cal and referenceAcinetobacter strains, 102 ofwhich
were previously speciated by ampliﬁed rDNA
restriction analysis as belonging to theAcinetobacter
calcoaceticus–A. baumannii complex, the method
correctly identiﬁed 31 A. baumannii and 54 Acinet-
obacter genomic sp. 13TU isolates to the species
level. The method was rapid, speciﬁc and easy to
interpret.
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Members of the genus Acinetobacter are now
recognised as important nosocomial pathogens,
with Acinetobacter baumannii, in particular, caus-
ing serious problems in the intensive care unit
setting because of its innate and acquired antimi-
crobial resistance and its tendency for epidemic
spread. The unnamed Acinetobacter genomic
spp. 3 and 13TU are also involved in nosocomial
infections, but to a lesser extent. These three
species are commonly grouped with the environ-
mental organism Acinetobacter calcoaceticus in the
A. calcoaceticus–A. baumannii complex because
of the difﬁculty in separating these species
using phenotypic methods [1,2]. Manual and
semi-automated commercial identiﬁcation sys-
tems, e.g., API 20NE, VITEK 2, Phoenix and
MicroScan WalkAway, do not differentiate
among these species, resulting in misidentiﬁca-
tion of c. 25% of Acinetobacter isolates belonging
to the A. calcoaceticus–A. baumannii complex as
A. baumannii [3], and there is no recognised
biochemical method to distinguish reliably be-
tween A. baumannii and genomic sp. 13TU [1].
DNA–DNA hybridisation is the reference stan-
dard method to differentiate among these species,
but this technique is very laborious and is not
used routinely. Of the PCR-based methods,
ampliﬁed rDNA restriction analysis is recognised
as providing good discrimination, but can be
time-consuming, while tRNA ﬁngerprinting does
not discriminate between A. baumannii and geno-
mic sp. 13TU [4,5]. More recently, sequencing of
the rpoB gene and its ﬂanking spacer regions, and
of the 16S)23S rRNA gene spacer region, have
been proposed for identiﬁcation of Acinetobacter
isolates to the species level [6,7], but it is unlikely
that these sequencing techniques will be used
routinely, except in a few specialised reference
laboratories.
As part of an ongoing project to evaluate a
multilocus sequence typing scheme forA. bauman-
nii and genomic sp. 13TU, interspecies heterogene-
ity was observed in the gyrB gene. The working
hypothesis of the present study was that this could
be exploited to develop a PCR-based method to
differentiate between these two genomic species.
In total, 118 clinical, type and reference strains
were used. These comprised 31 A. baumannii and
54 Acinetobacter genomic sp. 13TU clinical isolates
(epidemiologically unrelated by pulsed-ﬁeld gel
electrophoresis) [3,8], the A. baumannii type strain
ATCC 19606TT, Acinetobacter genomic sp. 3 (13
isolates), A. calcoaceticus (3), Acinetobacter haemo-
lyticus (2), Acinetobacter johnsonii (2), Acinetobacter
junii (3), Acinetobacter lwofﬁi (4), Acinetobacter
radioresistens (3), Acinetobacter genomic sp. 6 (1)
and Acinetobacter genomic sp. 10 (1). The type
strains A. calcoaceticus ATCC 23055T, A. johnsonii
ATCC 17909T, A. junii ATCC 17908T, A. lwofﬁi
ATCC 13509T, A. radioresistens SEIP 12.81, geno-
mic sp. 3 ATCC 19004T, genomic sp. 6
ATCC 17979T, genomic sp. 9 ATCC 9957T and
genomic sp. 10 ATCC 17924T were included. Clin-
ical isolates had been identiﬁed previously to the
Corresponding author and reprint requests: H. Seifert, Institute
for Medical Microbiology, Immunology and Hygiene, Univer-
sity of Cologne, Goldenfelsstr. 19-21, 50935 Cologne, Germany
E-mail: harald.seifert@uni-koeln.de
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases
species level using ampliﬁed rDNA restriction
analysis [5] and the simpliﬁed phenotypic iden-
tiﬁcation scheme for Acinetobacter spp. devised by
Bouvet and Grimont [9].
The gyrB gene sequences from A. baumannii
and Acinetobacter genomic sp. 13TU were aligned
and three primers were designed; two were
universal to both species, sp4F (5¢-CACGCCGTA-
AGAGTGCATTA) and sp4R (5¢-AACGGAGCTT-
GTCAGGGTTA), and one differed at the 3¢ end
from genomic sp. 13TU, sp2F (5¢-GTTCCTGAT-
CCGAAATTCTCG). Gradient PCR was per-
formed to determine the optimum annealing
temperature for sp2F so that it would yield a
PCR product with A. baumannii, but not with
genomic sp. 13TU; thus, in a PCR with all three
primers, both A. baumannii and genomic sp. 13TU
would yield an amplicon of 294 bp (sp4F to sp4R)
but only A. baumannii would yield a second
amplicon of 490 bp (sp2F to sp4R). The eventual
multiplex PCR was performed using Taq PCR
Master Mix (Qiagen, Hilden, Germany), with a
ﬁnal volume of 25 lL or 50 lL and primer
concentrations of 0.2 lM. Ampliﬁcation com-
prised 94C for 2 min, followed by 25 cycles of
94C for 1 min, 60C for 30 s and 72C for 1 min,
with a ﬁnal extension at 72C for 10 min. PCR
products were analysed on agarose 1.2% w ⁄ v
gels, stained with ethidium bromide, and visual-
ised on a UV transilluminator.
PCR with the three-primer mix identiﬁed all 32
A. baumannii isolates correctly. In every case, two
clear bands were visible on agarose gels, while all
54 genomic sp. 13TU isolates yielded only the
lower 294-bp band (Fig. 1). The remaining 32
Acinetobacter isolates (i.e., belonging to genomic
species other than A. baumannii and genomic
sp. 13TU) failed to produce any PCR products.
No false-positive or false-negative reactions were
observed. Results were obtained in <2.5 h from an
agar plate to a ﬁnished gel, and identiﬁcation
could be achieved with either puriﬁed DNA or
crude cell lysates.
The use of gyrB as a means to identify Acinet-
obacter isolates to the species level is not new. It
was demonstrated over a decade ago that nucle-
otide and amino-acid sequences can both be used
for taxonomic purposes, and that they correlate
with DNA–DNA hybridisation [10]. It was also
shown that A. baumannii and Acinetobacter genomic
sp. 13TU cluster together [11]. The gyrB gene
sequences of A. calcoaceticus and Acinetobacter
genomic sp. 3 also cluster together [11], thereby
allowing the possibility of expanding the present
PCR method to achieve complete differentiation
of the A. calcoaceticus–A. baumannii complex in a
single reaction.
The species that form the A. calcoaceticus–
A. baumannii complex have been grouped
together because they are genetically closely
related and phenotypically very difﬁcult to
differentiate from each other. However, there
are considerable epidemiological and clinically
relevant differences among these species.
A. calcoaceticus is an environmental organism
that, to our knowledge, has never been involved
in serious human disease, and which should
therefore not be misidentiﬁed as A. baumannii.
The natural habitats of A. baumannii and geno-
mic sp. 13TU are unknown, as are the differ-
ences in their epidemic behaviour, resistance
mechanisms and pathogenicity. Acinetobacter
genomic sp. 3 can be found regularly on human
skin, as well as in aquatic environments. Geno-
mic sp. 3 has been implicated in nosocomial
infections, but its tendency for epidemic spread
and resistance development is far less pro-
nounced than that of A. baumannii [8,12]. For
epidemiological and clinical purposes, it is
therefore highly desirable to differentiate among
these species correctly. At present, sufﬁcient gyrB
sequences for genomic sp. 3 are not available to
allow the expansion of the gyrB PCR method to
identify genomic sp. 3. For the time being,
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Fig. 1. Example of agarose gel showing Acinetobacter iso-
lates speciated by PCR using gyrB-directed primers. Lanes:
1, 100-bp ladder; 2, Acinetobacter baumannii ATCC 19606;
3–5, A. baumannii clinical isolates; 6–9, Acinetobacter geno-
mic sp. 13TU clinical isolates; 10, negative control with no
DNA template.
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isolates that are identiﬁed as A. baumannii by
commercial identiﬁcation methods, but that fail
to yield a PCR product, may be identiﬁed
tentatively as genomic sp. 3 if they grow at
41C but fail to grow at 44C.
The gyrB PCR method is robust and reproduc-
ible, and can yield a result in <2.5 h. Its simplicity
means that it can be employed readily in most
laboratories, where it should contribute to a better
understanding of the epidemiology and clinical
signiﬁcance of the two most important Acineto-
bacter species.
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ABSTRACT
This study describes the development of a real-
time PCR protocol for rapid detection of the most
common blaVIM (blaVIM-1, blaVIM-2, blaVIM-3, blaVIM-4,
blaVIM-5, blaVIM-6, blaVIM-10, blaVIM-11, blaVIM-12) and
blaIMP (blaIMP-1, blaIMP-2, blaIMP-6, blaIMP-8, blaIMP-10,
blaIMP-15, blaIMP-19, blaIMP-20) genes in a single
reaction. The genes were speciﬁcally detected
and clearly differentiated into four groups, i.e.,
(i)blaVIM-1-like (blaVIM-1,blaVIM-4,blaVIM-5,blaVIM-12);
(ii) blaVIM-2-like (blaVIM-2,blaVIM-3, blaVIM-6,blaVIM-10,
blaVIM-11); (iii) blaIMP-1-like (blaIMP-1, blaIMP-6,
blaIMP-10); and (iv) blaIMP-2-like (blaIMP-2, blaIMP-8,
blaIMP-15, blaIMP-19, blaIMP-20), by melting curve
analysis of the real-time PCR products. The
protocol was used to screen positive blaVIM-1,
blaVIM-2 and blaIMP-1 control strains, 70 Gram-
negative isolates resistant to carbapenems, and 30
Gram-negative isolates susceptible to carbapen-
ems (negative controls).
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